HEALTH● LOW1h ago · Oct 12, 2026, 2:20 PM
Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases
Seeking Alpha Tech · global
Mirum's drug Livmarli successfully met its primary objective in a Phase 3 clinical trial for treating itch associated with rare liver diseases. This represents a significant step in the development of a potential new treatment for these conditions.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH24m agoWHO probes ‘unanswered questions’ over Russian plague workerThe TelegraphHEALTH50m agoMan with glioblastoma continues to thrive 9 years after diagnosisCBS NewsHEALTH52m agoHealth secretaries seek merger with Health Department in Andhra Pradesh to ease workloadThe HinduHEALTH1h agoWorld Mental Health Day: NHRC seeks inclusion of human rights focus in strategic planPremium Times